Venous Thromboembolism Prophylaxis after Hematopoietic Cell Transplantation: Still a Challenge for Hematologists and Hemostasiologists

Publikationsverlauf

Eingereicht: 01. Oktober 2024

Angenommen: 02. Oktober 2024

Accepted Manuscript online:
04. Oktober 2024

Artikel online veröffentlicht:
11. November 2024

• References

• 1 Copelan EA, Chojecki A, Lazarus HM, Avalos BR. Allogeneic hematopoietic cell transplantation; the current renaissance. Blood Rev 2019; 34: 34-44
• 2 Lin RJ, Artz AS. Allogeneic hematopoietic cell transplantation for older patients. Hematology (Am Soc Hematol Educ Program) 2021; 2021 (01) 254-263
• 3 Sorror ML, Maris MB, Storb R. et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106 (08) 2912-2919
• 4 Granat LM, Li H, Ondeck M. et al. Venous thromboembolism post-alogeneic hematopoietic cell transplant: risk factors, incidence and outcomes. Thromb Haemost 2024
• 5 Zahid MF, Murad MH, Litzow MR. et al. Venous thromboembolism following hematopoietic stem cell transplantation-a systematic review and meta-analysis. Ann Hematol 2016; 95 (09) 1457-1464
• 6 Young JA, Pallas CR, Knovich MA. Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis. Bone Marrow Transplant 2021; 56 (08) 1805-1817
• 7 Gerber DE, Segal JB, Levy MY, Kane J, Jones RJ, Streiff MB. The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention. Blood 2008; 112 (03) 504-510
• 8 Annibali O, Napolitano M, Avvisati G, Siragusa S. Incidence of venous thromboembolism and use of anticoagulation in hematological malignancies: critical review of the literature. Crit Rev Oncol Hematol 2018; 124: 41-50
• 9 Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006; 24 (03) 484-490
• 10 Falanga A, Leader A, Ambaglio C. et al. EHA guidelines on management of antithrombotic treatments in thrombocytopenic patients with cancer. HemaSphere 2022; 6 (08) e750
• 11 Ibrahim RB, Peres E, Dansey R. et al. Safety of low-dose low-molecular-weight-heparins in thrombocytopenic stem cell transplantation patients: a case series and review of the literature. Bone Marrow Transplant 2005; 35 (11) 1071-1077
• 12 Khanal N, Bociek RG, Chen B. et al. Venous thromboembolism in patients with hematologic malignancy and thrombocytopenia. Am J Hematol 2016; 91 (11) E468-E472
• 13 Key NS, Khorana AA, Kuderer NM. et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 2020; 38 (05) 496-520
• 14 Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111 (10) 4902-4907
• 15 Lee A, Badgley C, Lo M. et al. Evaluation of venous thromboembolism prophylaxis protocol in hematopoietic cell transplant patients. Bone Marrow Transplant 2023; 58 (11) 1247-1253
• 16 Martens KL, da Costa WL, Amos CI. et al. HIGH-2-LOW risk model to predict venous thromboembolism in allogeneic transplant patients after platelet engraftment. Blood Adv 2021; 5 (01) 167-175
• 17 Gangaraju R, Chen Y, Hageman L. et al. Late-occurring venous thromboembolism in allogeneic blood or marrow transplant survivors: a BMTSS-HiGHS2 risk model. Blood Adv 2021; 5 (20) 4102-4111
• 18 Li A, Martens KL, Nguyen D. et al. External validation of the HIGH-2-LOW model: a predictive score for venous thromboembolism after allogeneic transplant. Am J Hematol 2022; 97 (06) 740-748
• 19 Nevo S, Enger C, Swan V. et al. Acute bleeding after allogeneic bone marrow transplantation: association with graft versus host disease and effect on survival. Transplantation 1999; 67 (05) 681-689
• 20 El Jurdi N, Elhusseini H, Beckman J. et al. High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group. Blood Cancer J 2021; 11 (05) 96
• 21 Agnelli G, Becattini C, Meyer G. et al; Caravaggio Investigators. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020; 382 (17) 1599-1607
• 22 McBane II RD, Wysokinski WE, Le-Rademacher JG. et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost 2020; 18 (02) 411-421
• 23 Noumegni SR, Mansourati V, Tromeur C. et al. Risk factors of cardiovascular death after venous thromboembolism: results from a prospective cohort study. Thromb Haemost 2022; 122 (10) 1744-1756
• 24 Danilatou V, Dimopoulos D, Kostoulas T, Douketis J. Machine learning-based predictive models for patients with venous thromboembolism: a systematic review. Thromb Haemost 2024; 124 (11) 1040-1052
• 25 Gorog DA, Gue YX, Chao TF. et al. Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: executive summary of a European and Asia-Pacific Expert Consensus Paper. Thromb Haemost 2022; 122 (10) 1625-1652
• 26 Olie RH, Winckers K, Rocca B, Ten Cate H. Oral anticoagulants beyond warfarin. Annu Rev Pharmacol Toxicol 2024; 64: 551-575